<DOC>
	<DOCNO>NCT02187926</DOCNO>
	<brief_summary>The purpose study examine characteristic patient select treatment roflumilast effectiveness safety roflumilast patient severe severe COPD treat Hospital outpatient specialist ward setting Greece .</brief_summary>
	<brief_title>Evaluation Clinical Effectiveness Roflumilast Routine Practice , Chronic Obstructive Pulmonary Disease ( COPD ) Patients Greece</brief_title>
	<detailed_description>The drug observe study call roflumilast . Roflumilast use treat people chronic obstructive pulmonary disease ( COPD ) associate chronic bronchitis history worsen symptom . This study look side effect lung function people take roflumilast . The study enrol 2577 patient already prescribe roflumilast add bronchiodilator treatment healthcare provider . This multi-centre trial conduct Greece . The overall time participate study 6 month . Participants evaluate routine appointment healthcare provider .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Inclusion Criteria Be diagnose COPD stag 3 4 accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) guideline . Have clinical phenotype chronic bronchitis cough sputum production ( without emphysema ) . Already receive treatment disease ( inhaled bronchodilator ( longacting beta2agonists ( LABA ) , longacting muscarinic antagonist ( LAMA ) , shortacting beta2agonists ( SABA ) , shortacting muscarinic antagonist ( SAMA ) ) , inhaled corticosteroid ( ICS ) , combination inhale bronchodilator corticosteroid . Be age 40 year â€¢ None</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>